ACAD
Acadia Pharmaceuticals Inc

13,121
Mkt Cap
$4.72B
Volume
238,804.00
52W High
$28.35
52W Low
$13.40
PE Ratio
17.93
ACAD Fundamentals
Price
$27.61
Prev Close
$27.87
Open
$27.87
50D MA
$24.22
Beta
0.95
Avg. Volume
1.6M
EPS (Annual)
$1.36
P/B
5.14
Rev/Employee
$1.46M
Loading...
Loading...
News
all
press releases
ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. trimmed its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 98.4% during the 3rd quarter, according to its most recent disclosure with...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Here's Why
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Should You Buy...
MarketBeat·4d ago
News Placeholder
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·4d ago
News Placeholder
Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD
Hohimer Wealth Management LLC decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 26.6% during the 2nd quarter, according to its most recent disclosure with the SEC...
MarketBeat·12d ago
News Placeholder
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD
TFG Asset Management GP Ltd raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 50.8% in the 2nd quarter, according to its most recent Form 13F filing with the...
MarketBeat·13d ago
News Placeholder
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Eventide Asset Management LLC decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 14.6% in the second quarter, according to its most recent Form 13F filing...
MarketBeat·13d ago
News Placeholder
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Birchview Capital LP lessened its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 28.7% in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·13d ago
News Placeholder
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free...
Business Wire·14d ago
News Placeholder
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $928,000 Position in ACADIA Pharmaceuticals Inc. $ACAD
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the second quarter, according...
MarketBeat·14d ago
News Placeholder
Stifel Nicolaus Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price
Stifel Nicolaus boosted their target price on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a "hold" rating in a research note on Thursday...
MarketBeat·15d ago
<
1
2
...
>

Latest ACAD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.